Stereotactic body radiotherapy for lung oligometastatic prostate cancer: An international retrospective multicenter study
- Author(s)
- Rogé, M; Bowden, P; Conway, P; Franzese, C; Scorsetti, M; Seront, E; Blanchard, P; Terlizzi, M; Khalifa, J; Pasquier, C; Shick, U; Siva, S; Paul, J; Supiot, S;
- Journal Title
- Clinical and Translational Radiation Oncology
- Publication Type
- Research article
- Abstract
- BACKGROUND: Management of prostate cancer (PCa) patients with lung oligometastases remains unclear in the absence of published data. OBJECTIVE: The aim of this study was to evaluate the efficacy of Stereotactic Body Radiotherapy (SBRT) in this setting. DESIGN SETTING AND PARTICIPANTS: We conducted a multicenter retrospective study that included 35 PCa patients treated with SBRT for lung oligometastases in 7 centers across 3 countries. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The efficacy was evaluated by the progression free-survival (PFS), defined as pre-SBRT PSA + 25 % or nadir PSA + 25 % and + 2 ng/mL or radiological progression if it occurred before biochemical progression. The local recurrence free-survival (LRFS), distant metastases free-survival (DMFS), Overall Survival (OS) and Androgen Deprivation Therapy free-survival were also assessed. Survival was estimated using the Kaplan Meier method. RESULTS: 35 patients were included with lung oligometastases staged with PET-CT for 97 % and histologically biopsy confirmed for 51 %. 77 % had an oligorecurrent metastatic disease. The median pre SBRT PSA was at 1.7 ng/mL [0.8, 3.0] and the median follow-up after SBRT was 28.7 months. The median PFS was 21.6 months [95 %CI: 21.6; NA] and the median DMFS was 32.4 months [95 %CI: 22.2-NA]. No parameters were significantly associated with PFS on the univariate and multivariate models.For patients who did not start ADT before or concomitantly with SBRT (n = 18), the 1-year ADT free-survival rate was estimated at 87.2 % [71.9;100]. CONCLUSIONS: SBRT for PCa lung oligometastases offers good oncological outcomes, comparable to those reported for bone and/or lymph node metastases SBRT. Our results encourage the inclusion of patients with lung oligometastatic disease in clinical trials designed to assess the value of SBRT. PATIENT SUMMARY: SBRT for prostate cancer lung oligometastases shows promising results, similar to treatments for bone or lymph node oligometastases.
- Publisher
- Elsevier
- Keywords
- Androgen deprivation therapy; Biochemical progression free survival; Lung metastases; Oligometastases; Prostate cancer; Stereotactic body radiotherapy
- Department(s)
- Radiation Oncology
- Publisher's Version
- https://doi.org/10.1016/j.ctro.2025.100944
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-04-15 07:53:09
Last Modified: 2025-04-15 07:53:18